



ASX ANNOUNCEMENT:

2020 Annual Meeting of Stockholders

16 April 2020 – Melbourne, Australia and Minnesota, United States – Osprey Medical (ASX:OSP) refers to its previous ASX announcements relating to the Company’s Annual Meeting of Stockholders (**Annual Meeting**) where the Company advised that its Annual Meeting would be held on Wednesday, 13 May 2020. As a result of the COVID-19 pandemic and having regard to the imposition of restrictions and limits on public gatherings in the United States and Australia, the Company has elected to defer its Annual Meeting to a date to be determined while it considers alternative meeting dates and options by which the meeting can be conducted to allow for an appropriate level of participation by shareholders and CHESS Depository Interest holders. A further announcement will be made when an alternative date has been determined.

This announcement has been approved by the President & Chief Executive Officer, Mike McCormick.

– ENDS –

Contact details:

Media

Dr Thomas Duthy
Nemean Group
M: (61) 402 493 727

tduthy@ospreymed.com

Company

Brendan Case
Company Secretary
M: (61) 410 442 393

brendan@casegovernance.com.au

About Osprey Medical (ASX: OSP)

Osprey Medical’s vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient’s risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company’s core technologies originated from research conducted by Dr David Kaye at Melbourne’s Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company’s DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical’s Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical’s advisory board comprises world-recognised experts in heart and kidney diseases.

Foreign Ownership Restriction

Osprey’s CHESS Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state

or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

US OFFICE & HEADQUARTERS: 7600 Executive Drive | Eden Prairie MN 55344 | Tel: +1 952.955.8230 | Fax: +1 952.955.8171 |
AUSTRALIAN OFFICE: Professional Chambers, Level 2, 120 Collins Street | Melbourne VIC 3000 | Tel: +61 410 442 393 | Fax: +61 3 9663 6609 |
Osprey Medical Inc. (ARBN 152 854 923) is a foreign company incorporated in Delaware, USA,
whose stockholders have limited liability.
www.ospreymed.com

Error! Unknown document property name.